UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35

Benzinga · 3d ago
UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.